Navigation Links
Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
Date:3/20/2008

SUNRISE, Fla., March 20 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) will report financial results for the year ended December 31, 2007 after the close of the market on Thursday, March 27, 2008. The Company has scheduled a conference call for Thursday, March 27, 2008 at 4:30 p.m. Eastern to discuss these results.

Interested parties can access the call by dialing (877) 858-9308 or (706) 643-0580, or can listen via a live Internet web cast, which can be found at http://www.bioheartinc.com. A replay of the call is available via webcast at http://www.bioheartinc.com for 30 days or by playback at (800) 642-1687 or (706) 645-9291 through March 29, 2008. Please use conference id #: 39978839 for the replay.

About Bioheart, Inc.:

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell II with SDF-1(TM), a therapy utilizing autologous cells genetically modified to express additional growth factors.

MyoCell and MyoCell II with SDF-1 are registered trademarks of Bioheart, Inc.

Contact: William Kline Lytham Partners, LLC

Chief Financial Officer Joe Diaz

Nicholas Burke Joe Dorame

VP - Financial Operations Robert Blum

(954) 835-1500 (602) 889-9700


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
2. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
3. Vion Reports 2007 Fourth Quarter and Year-End Results
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports the Death of Its Director James Andress
7. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Unigene Restates Policy on Analyst Reports
10. NPS Pharmaceuticals Reports 2007 Financial Results
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing ... disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):